---
title: 'Definitions and use of tumour bulk in phase 3 lymphoma trials: a comprehensive
  literature review'
date: '2025-01-18'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39825862/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20250118170356&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: Tumour 'bulk' has historically been considered an important prognostic
  marker and clinical tool to guide treatment in patients with lymphoma. However,
  its use and definitions in trial designs varies significantly and it is unclear
  how this has influenced the relevance of bulk in contemporary practice. This comprehensive
  literature review evaluated the definitions, applications and prognostic impact
  of bulk in phase 3 randomised trials in four major lymphoma subtypes. Overall, 87
  studies ...
disable_comments: true
---
Tumour 'bulk' has historically been considered an important prognostic marker and clinical tool to guide treatment in patients with lymphoma. However, its use and definitions in trial designs varies significantly and it is unclear how this has influenced the relevance of bulk in contemporary practice. This comprehensive literature review evaluated the definitions, applications and prognostic impact of bulk in phase 3 randomised trials in four major lymphoma subtypes. Overall, 87 studies ...